Physician profile
William E Smoyer
NPI 1659387827
$160,931.68
in general payments reported to CMS, 2019-2025
12 companies · $23K in 2025
The $23K reported for 2025 was more than what 96% of Pediatric Nephrology providers received nationally (typical 2025 total: $131).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,271 · 2021: $12K · 2022: $13K · 2023: $4,778 · 2024: $101K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $121K · Travel and Lodging: $4,429 · Food and Beverage: $2,375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $121,242.66 |
| Travel and Lodging | $4,428.68 |
| Food and Beverage | $2,375.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $57,057.39 | 2022-2025 | |
| Boehringer Ingelheim International Gmbh | $45,611.61 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $25,910.35 | 2023-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21,825.93 | 2021-2025 | |
| Pfizer INC. | $7,211.29 | 2019 | |
| Otsuka Pharmaceutical Co., Ltd. | $2,625.00 | 2021 | |
| Apellis Pharmaceuticals, INC. | $310.98 | 2025 | Empaveli |
| Aurinia Pharma U.S., INC. | $257.78 | 2022-2024 | Lupkynis |
| Astrazeneca Pharmaceuticals Lp | $47.75 | 2021 | |
| Mallinckrodt Enterprises LLC | $33.25 | 2019 | |
| Kaneka Medical America LLC | $26.33 | 2019 | |
| Nuwellis, INC. | $14.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Smoyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.